Choi Ji Eun, Hyun Chang Lim, Jin Min-Sun, Lee Kyung-Min, Moon Ji Hye, Ryu Han Suk
Department of Pathology, Design Hospital, Jeonju, Korea.
Department of Pathology, Jeju National University Hospital, Jeju, Korea.
J Breast Cancer. 2020 Feb;23(1):36-46. doi: 10.4048/jbc.2020.23.e12.
We investigated the expression of the N-myc and STAT interactor (NMI) protein in invasive ductal carcinoma tissue and estimated its clinicopathologic significance as a prognostic factor. The expression levels and prognostic significance of NMI were also analyzed according to the molecular subgroup of breast cancers.
Human NMI detection by immunohistochemistry was performed using tissue microarrays of 382 invasive ductal carcinomas. The correlation of NMI expression with patient clinicopathological parameters and prognostic significance was analyzed and further assessed according to the molecular subgroup of breast cancers. Moreover, experiments with 13 breast cancer cell lines were carried out. We also validated NMI expression significance in The Cancer Genome Atlas cohort using the Human Protein Atlas (HPA) database.
Low NMI expression was observed in 190 cases (49.7%). Low NMI expression was significantly associated with the "triple-negative" molecular subtype ( < 0.001), high nuclear grade ( < 0.001), high histologic grade ( < 0.001), and advanced anatomic stage ( = 0.041). Patients with low NMI expression had poorer progression-free survival ( = 0.038) than patients with high NMI expression. Low NMI expression was not significantly associated with patient prognosis in the molecular subgroup analysis. , a reduction of NMI expression was observed in 8 breast cancer cell lines, especially in the estrogen receptor-positive and basal B type of triple-negative breast cancer molecular subgroups. The HPA database showed that low NMI expression levels were associated with a lower survival probability compared with that associated with high NMI expression ( = 0.053).
NMI expression could be a useful prognostic biomarker and a potential novel therapeutic target in invasive ductal carcinoma.
我们研究了N - myc和信号转导及转录激活因子相互作用分子（NMI）蛋白在浸润性导管癌组织中的表达情况，并评估其作为预后因素的临床病理意义。还根据乳腺癌的分子亚组分析了NMI的表达水平及预后意义。
使用382例浸润性导管癌的组织芯片通过免疫组织化学检测人NMI。分析NMI表达与患者临床病理参数的相关性及预后意义，并根据乳腺癌的分子亚组进一步评估。此外，对13种乳腺癌细胞系进行了实验。我们还使用人类蛋白质图谱（HPA）数据库在癌症基因组图谱队列中验证了NMI表达的意义。
190例（49.7%）观察到低NMI表达。低NMI表达与“三阴性”分子亚组显著相关（<0.001）、高核分级（<0.001）、高组织学分级（<0.001）及晚期解剖学分期（=0.041）。低NMI表达的患者无进展生存期比高NMI表达的患者差（=0.038）。在分子亚组分析中，低NMI表达与患者预后无显著相关性。在8种乳腺癌细胞系中观察到NMI表达降低，尤其是在雌激素受体阳性和三阴性乳腺癌分子亚组的基底B型中。HPA数据库显示，与高NMI表达相比，低NMI表达水平与较低的生存概率相关（=0.053）。
NMI表达可能是浸润性导管癌中一种有用的预后生物标志物和潜在的新型治疗靶点。
